< Back to latest news & events

Event

Translational Microbiome Conference 2020

April 2020

Event date: 24th April 2020

Translational Microbiome Conference 2020 will be hosted on 21-24 April. It will bring together the leading microbiome companies working to successfully commercialise microbiome-based diagnostics, therapeutics, adjunct therapies and direct-to-consumer services and products across a range of therapeutic areas, from gut to skin and beyond.

The conference will focus on the challenges and hurdles that companies working in the microbiome space will have to recognise and navigate in order to successfully commercialise their products.

HGF Partner Craig Thomson will be hosting a panel discussion:

Getting your bugs in a row: preparing your IP for investment

Intellectual Property (IP) is only one of the things that investors look at when deciding to invest. How important is IP to investors? What questions can you expect to be asked of your IP? We will also explore what can be done in advance to make it easier to clearly and efficiently demonstrate to investors that your IP adequately underpins the business seeking investment (and how this can be done when funds are tight). The panel will consist of investors, microbiome professionals that are experienced at obtaining large and small level investments, and those that have assisted investors to review IP portfolios as part of pre-investment due diligence.

Attendees

Latest updates

Event - 12th September 2025

Wolters Kluwer Breakfast Panel on AI & IP at AIPPI

Sofie McPherson, Patent Director at HGF, will be moderating a special breakfast panel session hosted by Wolters Kluwer at the AIPPI World Congress in Yokohama on 15 September 2025. Session …

Event details

T1465/23 – No Narrowing by Description—EPO Board Terminates Inventive Step Analysis for Arbitrary Modifications Citing G1/24 and G1/19

“The potential patentability of a specific narrow embodiment…cannot render a claim allowable which, due to its breadth, encompasses a multitude of other, non-inventive embodiments” – r. 3.5. Background EP3113515 was …

Read article

Wrestling with G1/24 – How should the claims be interpreted in view of the description?

In G1/24, the Enlarged Board of Appeal (EBA) codified how claims should be interpreted for assessing patentability: in consultation with the description. However, the decision was light on how, in …

Read article

Welcome to HGF Presents - New Video Series

Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …

Read article

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

Providing Enabling Disclosure for AI inventions at the EPO

  Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …

Read article

Personalised Medicine Patenting of Known Drugs for Known Indications at the EPO

Video overview: The identification of specific sub-groups of patients to treat with a known drug, even if said patients may have been treated before with the drug, can yield patentable …

Read article